RT Journal Article
SR Electronic
T1 Quantifying SARS-CoV-2 spread in Switzerland based on genomic sequencing data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.14.20212621
DO 10.1101/2020.10.14.20212621
A1 Nadeau, Sarah
A1 Beckmann, Christiane
A1 Topolsky, Ivan
A1 Vaughan, Timothy
A1 Hodcroft, Emma
A1 Schär, Tobias
A1 Nissen, Ina
A1 Santacroce, Natascha
A1 Burcklen, Elodie
A1 Ferreira, Pedro
A1 Jablonski, Kim Philipp
A1 Posada-Céspedes, Susana
A1 Capece, Vincenzo
A1 Seidel, Sophie
A1 de Souza, Noemi Santamaria
A1 Martinez-Gomez, Julia M.
A1 Cheng, Phil
A1 Bosshard, Philipp P.
A1 Levesque, Mitchell P.
A1 Kufner, Verena
A1 Schmutz, Stefan
A1 Zaheri, Maryam
A1 Huber, Michael
A1 Trkola, Alexandra
A1 Cordey, Samuel
A1 Laubscher, Florian
A1 Gonçalves, Ana Rita
A1 Leuzinger, Karoline
A1 Stange, Madlen
A1 Mari, Alfredo
A1 Roloff, Tim
A1 Seth-Smith, Helena
A1 Hirsch, Hans H.
A1 Egli, Adrian
A1 Redondo, Maurice
A1 Kobel, Olivier
A1 Noppen, Christoph
A1 Beerenwinkel, Niko
A1 Neher, Richard A.
A1 Beisel, Christian
A1 Stadler, Tanja
YR 2020
UL http://medrxiv.org/content/early/2020/10/30/2020.10.14.20212621.abstract
AB Pathogen genomes provide insights into their evolution and epidemic spread. We sequenced 1,439 SARS-CoV-2 genomes from Switzerland, representing 3-7% of all confirmed cases per week. Using these data, we demonstrate that no one lineage became dominant, pointing against evolution towards general lower virulence. On an epidemiological level, we report no evidence of cryptic transmission before the first confirmed case. We find many early viral introductions from Germany, France, and Italy and many recent introductions from Germany and France. Over the summer, we quantify the number of non-traceable infections stemming from introductions, quantify the effective reproductive number, and estimate the degree of undersampling. Our framework can be applied to quantify evolution and epidemiology in other locations or for other pathogens based on genomic data.One Sentence Summary We quantify SARS-CoV-2 spread in Switzerland based on genome sequences from our nation-wide sequencing effort.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSN and TS are supported by the Swiss National Science Foundation (grant number 31CA30_196267).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequence data used is available on https://www.gisaid.org/.